INTRON A VS INTRON A + RIBAVIRIN IN RELAPSED HEPATITIS C

内含子 A 与内含子 A 利巴韦林治疗复发性丙型肝炎的比较

• 批准号: 6118118
• 负责人: John G. McHutchison
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118118
• 关键词: clinical research; clinical trials; combination chemotherapy; hepatitis C; hepatitis C virus; human subject; human therapy evaluation; immunotherapy; interferon alpha; microorganism disease chemotherapy; relapse /recurrence; ribavirin

This study addresses the efficacy and safety of interferon alpha-2b compared to interferon alpha-2b and Ribavirin in untreated hepatitis C patients. The biochemical and virological response to treatment are measured at two time points: at the end of treatment and six months posttreatment sustained response. Secondary endpoints include improve- ment in liver biopsy at posttreatment (based on the sum of Knodell scores I+II+III), time to response and time to relapse. This randomized clinical trial continues and no preliminary results are available. Future studies will focus on a long-acting form of pegylated interferon in conjunction with ribavirin.

本研究探讨了干扰素α-2b与干扰素α-2b和利巴韦林在未经治疗的丙型肝炎患者中的疗效和安全性。 在两个时间点测量对治疗的生物化学和病毒学应答：治疗结束时和治疗后6个月的持续应答。 次要终点包括治疗后肝活检的改善（基于Knodell评分I+II+III的总和）、至缓解时间和至复发时间。 这项随机临床试验仍在继续，目前尚无初步结果。 未来的研究将集中在长效形式的聚乙二醇干扰素联合利巴韦林。